Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Oncogene

• Publication date

  2010-01-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/onc.2009.306PMID 19802013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Combination of Proteasome and HDAC Inhibitors for Uterine Cervical Cancer Treatment

  2009cited by this paper
• Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.

  2009cited by this paper
• Prognostic Value of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer

  2009cited by this paper
• Time for epigenetics.

  2009cited by this paper
• Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.

  2009cited by this paper
• Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.

  2009cited by this paper
• TRAIL receptor signalling and modulation: Are we on the right TRAIL?

  2009cited by this paper
• Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells

  2008cited by this paper
• Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

  2008cited by this paper
• A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

  2008cited by this paper
• Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells

  2008cited by this paper
• HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2.

  2008cited by this paper
• HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias.

  2008cited by this paper
• The TRAIL apoptotic pathway in cancer onset, progression and therapy

  2008cited by this paper
• Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.

  2008cited by this paper
• Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer.

  2008cited by this paper
• Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

  2008cited by this paper
• Clearing the TRAIL for Cancer Therapy.

  2007cited by this paper
• Vorinostat in cutaneous T-cell lymphoma.

  2007cited by this paper
• Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies

  2007cited by this paper
• HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics

  2007cited by this paper
• FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

  2007cited by this paper
• HDAC inhibitors: clinical update and mechanism-based potential.

  2007cited by this paper
• Histone deacetylase inhibitors: molecular mechanisms of action

  2007cited by this paper
• Feijoa sellowiana derived natural Flavone exerts anti-cancer action displaying HDAC inhibitory activities.

  2007cited by this paper
• MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent.

  2007cited by this paper
• NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells.

  2007cited by this paper
• Discovery and development of SAHA as an anticancer agent

  2007cited by this paper
• The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.

  2006cited by this paper
• Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

  2006cited by this paper
• Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.

  2006cited by this paper
• Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.

  2006cited by this paper
• Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

  2006cited by this paper
• UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas

  2005cited by this paper
• Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

  2005cited by this paper
• Drug Insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid

  2005cited by this paper
• Acute myeloid leukemia: therapeutic impact of epigenetic drugs.

  2005cited by this paper
• ERRATUM: Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene

  2005cited by this paper
• Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer

  2005cited by this paper
• Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.

  2005cited by this paper
• Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

  2005cited by this paper
• Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

  2005influential reference
• BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.

  2003cited by this paper
• Targeting death and decoy receptors of the tumour-necrosis factor superfamily

  2002cited by this paper
• Histone deacetylases and cancer: causes and therapies

  2001cited by this paper
• Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL

  2001cited by this paper
• Translating the Histone Code

  2001cited by this paper
• Cytokine production by a new undifferentiated human thyroid carcinoma cell line, FB-1.

  1997cited by this paper
• High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.

  1993cited by this paper
• The Kirsten murine sarcoma virus induces rat thyroid carcinomas in vivo.

  1989cited by this paper
• One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes

  1987cited by this paper

• Post-translational modifications in anaplastic thyroid carcinoma: biological mechanisms and therapeutic potential

  2025cites this paper
• Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance

  2025cites this paper
• Epigenetics in thyroid cancer: a bibliometric analysis

  2024cites this paper
• ACAP3 negatively regulated by HDAC2 inhibits the malignant development of papillary thyroid carcinoma cells.

  2024cites this paper
• Histone deacetylase inhibitors: targeting epigenetic regulation in the treatment of acute leukemia

  2024cites this paper
• Mechanisms of mesothelial cell response to viral infections: HDAC1-3 inhibition blocks poly(I:C)-induced type I interferon response and modulates the mesenchymal/inflammatory phenotype

  2024cites this paper
• HDACs as an emerging target in endocrine tumors: a comprehensive review

  2023cites this paper
• Histone acetylation modifications: A potential targets for the diagnosis and treatment of papillary thyroid cancer

  2022cites this paper
• Gene Editing with CRISPR/Cas Methodology and Thyroid Cancer: Where Are We?

  2022cites this paper
• Efficacy and Safety Profile of Histone Deacetylase Inhibitors for Metastatic Breast Cancer: A Meta-Analysis

  2022cites this paper
• Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors

  2022cites this paper
• Apoptosis Activation in Thyroid Cancer Cells by Jatrorrhizine-Platinum(II) Complex via Downregulation of PI3K/AKT/Mammalian Target of Rapamycin (mTOR) Pathway

  2020cites this paper
• Synergy of GSK-J4 With Doxorubicin in KRAS-Mutant Anaplastic Thyroid Cancer

  2020cites this paper
• Improving TRAIL-induced apoptosis in cancers by interfering with histone modifications

  2020cites this paper
• Emerging Role of Protein Post-Translational Modification in the Potential Clinical Application of Cancer

  2020cites this paper
• Pharmacoepigenetics of Histone Deacetylase Inhibitors in Cancer

  2019cites this paper
• Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma

  2019cites this paper
• Immune Checkpoint Molecules and Cancer Immunotherapy

  2019cites this paper
• Therapeutic advances in anaplastic thyroid cancer: a current perspective

  2018cites this paper
• Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells

  2018cites this paper
• Histone deacetylase inhibitors as a new anticancer option : How far can we go with expectations ?

  2018cites this paper
• Checkpoint Blockade Rescues the Repressive Effect of Histone Deacetylases Inhibitors on γδ T Cell Function

  2018cites this paper
• Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes

  2018cites this paper
• Natural Agents-Mediated Targeting of Histone Deacetylases

  2018cites this paper
• Targeting post-translational histone modifications for the treatment of non-medullary thyroid cancer.

  2017cites this paper
• Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer.

  2017cites this paper
• Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases

  2017cites this paper
• Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer

  2016cites this paper
• Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Against Medullary Thyroid Cancer?

  2016cites this paper
• Histone deacetylase enzyme silencing using shRNAs enhances radiosensitivity of SW579 thyroid cancer cells

  2016cites this paper
• SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.

  2016cites this paper
• Potential Approaches to Chemotherapy of Thyroid Cancer in the Future

  2016cites this paper
• Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.

  2015cites this paper
• Vorinostat Enhance TRAIL-Induced Apoptosis Via DR5 in Anaplastic Thyroid Cancer Cells

  2015cites this paper
• Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer

  2015cites this paper
• Suppression of AKT Potentiates Synergistic Cytotoxicity of Apigenin with TRAIL in Anaplastic Thyroid Carcinoma Cells.

  2015cites this paper
• Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review

  2015cites this paper
• RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.

  2015cites this paper
• Role of ATF 3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic anti-DR 5 antibody through ER stress in human colon cancer cells

  2014cites this paper
• RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells

  2014cites this paper
• Regulation of TRAIL-Receptor Expression by the Ubiquitin-Proteasome System

  2014cites this paper
• High throughput screening identifies modulators of histone deacetylase inhibitors

  2014cites this paper
• Genetics and epigenetics of sporadic thyroid cancer.

  2014cites this paper
• Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic anti-DR5 antibody through ER stress in human colon cancer cells.

  2014cites this paper
• Class II HDAC Inhibition Hampers Hepatic Stellate Cell Activation by Induction of MicroRNA-29

  2013cites this paper
• Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment

  2013cites this paper
• Combination of Vorinostat and caspase‐8 inhibition exhibits high anti‐tumoral activity on endometrial cancer cells

  2013cites this paper
• Up-regulation of miR-146b and down-regulation of miR-200b contribute to the cytotoxic effect of histone deacetylase inhibitors on ras-transformed thyroid cells.

  2013cites this paper
• Heart failure: the pivotal role of histone deacetylases.

  2013cites this paper
• AY 4 , an agonistic anti-death receptor 4 MAB , induces apoptotic cell death in anaplastic thyroid cancer cells via downregulation of Bcl-xL with reactive oxygen species generation

  2013cites this paper
• AY4, an agonistic anti-death receptor 4 MAB, induces apoptotic cell death in anaplastic thyroid cancer cells via downregulation of Bcl-xL with reactive oxygen species generation.

  2013cites this paper
• Targeting histone deacetylase in thyroid cancer

  2013cites this paper
• Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585

  2012cites this paper
• Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.

  2012cites this paper
• Trials with ‘epigenetic’ drugs: An update

  2012cites this paper
• Targeted Therapy of Thyroid Cancer

  2012cites this paper
• Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells.

  2012cites this paper
• Antitumor Effects of Proteasome Inhibition in Anaplastic Thyroid Carcinoma

  2012cites this paper
• HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

  2012cites this paper
• HDAC inhibitor‐based therapies: Can we interpret the code?

  2012cites this paper
• HDACi

  2011cites this paper
• Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas.

  2011cites this paper
• Thyroid cancer--indications and opportunities for positron emission tomography/computed tomography imaging.

  2011cites this paper
• Signalling Pathways Leading to TRAIL Resistance

  2011cites this paper
• Epigenetics of thyroid cancer and novel therapeutic targets.

  2011cites this paper
• Alternative Medical Treatment for Radioiodine-Refractory Thyroid Cancers

  2011cites this paper
• Epigenetic multiple modulators.

  2011cites this paper
• Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells.

  2011cites this paper
• Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275

  2010cites this paper
• Targeted therapy for thyroid cancer: An updated review of investigational agents.

  2010cites this paper
• Targeting death receptors to fight cancer: from biological rational to clinical implementation.

  2010cites this paper
• Epigenetic drugs for cancer treatment and prevention: mechanisms of action

  2010cites this paper
• Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.

  2010cites this paper
• The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

  2010cites this paper
• Histone deacetylase inhibitors in Hodgkin lymphoma

  2010cites this paper